The Effect of Intradermal Acupuncture on Gallbladder Meridian Points on Cerebral Hemodynamics in Relevant Brain Regions for Major Depressive Disorder Based on fNIRS Technology

Sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05707299
Collaborator
(none)
40
1
2
15.9
2.5

Study Details

Study Description

Brief Summary

Gallbladder meridian(GB) acupoints may play an important role in the treatment of major depressive disorder (MDD). Therefore, this study is designed to focus on the traditional Chinese medicine (TCM) theory of " gallbladder dominating decision ", take the GB as the entry point, and use functional Near-Infrared Spectroscopy(fNIRS) technology to observe the effect of intradermal acupuncture on the cerebral hemodynamic indexes of the prefrontal cortex and bilateral temporal cortex of patients with MDD.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Intradermal acupuncture
N/A

Detailed Description

This study will include 20 patients with MDD (observation group) and 20 healthy control participants without MDD (control group). fNIRS will be adopted to assess regional oxygen saturation of the blood in the MDD-related cerebral cortex: the prefrontal and bilateral temporal cortex. Based on the results of the fNIRS, to explore cerebral hemodynamic changes in the prefrontal and bilateral temporal cortex in patients with MDD. By observing the changes of hemodynamic characteristics of the prefrontal cortex and bilateral temporal cortex of the observation group and the control group during the course of intradermal acupuncture, explore the immediate response of the hemodynamic characteristics of the prefrontal cortex and bilateral temporal cortex of the observation group to the intervention of the GB acupoints.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
The Effect of Intradermal Acupuncture on Gallbladder Meridian Points on Cerebral Hemodynamics in Relevant Brain Regions for Major Depressive Disorder Based on fNIRS Technology: Study Protocol of a Prospective, Single-center, Controlled Trial
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
May 31, 2024
Anticipated Study Completion Date :
May 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Observation group

This group will include 20 patients with MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.

Procedure: Intradermal acupuncture
Procedure/Surgery: Bilateral Fengchi(GB20)and Qiuxu(GB40) will be stimulated. According to the position of the acupoints, the needle of φ0.20*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of "resting- stimulating-preparing-stimulating-resting" to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi(GB20) for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu(GB40) for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level.

Other: Control group

This group will include 20 healthy control participants without MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.

Procedure: Intradermal acupuncture
Procedure/Surgery: Bilateral Fengchi(GB20)and Qiuxu(GB40) will be stimulated. According to the position of the acupoints, the needle of φ0.20*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of "resting- stimulating-preparing-stimulating-resting" to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi(GB20) for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu(GB40) for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level.

Outcome Measures

Primary Outcome Measures

  1. total hemoglobin (Total-Hb) [During the whole acupuncture operation]

    Total hemoglobin was calculated using the combined concentrations of oxygenated hemoglobin and deoxygenated hemoglobin [Total-Hb = oxy-Hb + deoxy-Hb].

  2. oxygenated hemoglobin (oxy-Hb) [During the whole acupuncture operation]

    Oxygenated hemoglobin is the combination of hemoglobin plus oxygen.

  3. deoxygenated hemoglobin (deoxy-Hb) [During the whole acupuncture operation]

    Deoxygenated hemoglobin is the unbound form of hemoglobin with oxygen.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 22 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Inclusion criteria for control group:
  1. Healthy control participants who could provide a recent depression screening report, and confirm they have not any cardiovascular, respiratory, digestive, urinary, hematological, endocrine, or neurological disease;

  2. 15 ≤ age ≤22 years, male or female;

  3. Participants have clear consciousness and could communicate with others normally;

  4. Participants could understand the full study protocol and have high adherence. Written informed consent is signed by adult participants themselves,and the minor participants is signed by a guardian;

  5. Participants should be right-handed;

Inclusion criteria for observation group:
  1. MDD patients should meet the diagnostic criteria of the International Classification of Diseases 11th Edition (ICD-11) diagnostic criteria for MDD;

  2. 15≤ age ≤22, male or female;

  3. Participants have clear consciousness and could communicate with others normally;

  4. Participants could understand the full study protocol and have high adherence. Written informed consent is signed by adult participants themselves,and the minor participants is signed by a guardian;

  5. Not taking antidepressants or antipsychotic drugs for at least 4 weeks before enrollment;

  6. Participants should be right-handed;

Exclusion Criteria:
Exclusion criteria for control group:
  1. Participants with serious primary diseases of cardiovascular diseases, liver diseases, kidney diseases, urinary diseases, and hematological diseases;

  2. Participants have an illness, alcohol dependence, or a history of drug abuse;

  3. Pregnant or lactating participants;

  4. Participants with intellectual disabilities who can't cooperate with the questionnaire survey;

  5. Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape;

  6. The test site of participants has scars, hyperpigmentation, red and swollen;

  7. Participants are participating in other trials;

Exclusion criteria for observation group:
  1. Participants with serious primary diseases of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, neurological disease, and other serious primary diseases, and the disease cannot be effectively controlled clinically;

  2. MDD caused by organic mental disorders, schizophrenia, bipolar disorder, psychoactive substances, and non-addictive substances;

  3. Participants with suicidal tendencies;

  4. Pregnant or lactating participants;

  5. Participants with intellectual disabilities who cannot cooperate with the questionnaire survey;

  6. Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape;

  7. The skin at the test site of participants has scars, hyperpigmentation, red and swollen;

  8. Participants are participating in other trials;

Contacts and Locations

Locations

Site City State Country Postal Code
1 the Third affiliated hospital of Zhejiang Chinese Medical university [Recruiting] Hangzhou Zhejiang China

Sponsors and Collaborators

  • The Third Affiliated hospital of Zhejiang Chinese Medical University

Investigators

  • Principal Investigator: Xiaomei Shao, Ph.D, The Third Affiliated hospital of Zhejiang Chinese Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xiaomei Shao, Prof, The Third Affiliated hospital of Zhejiang Chinese Medical University
ClinicalTrials.gov Identifier:
NCT05707299
Other Study ID Numbers:
  • 2022ZX010-fNIRS
First Posted:
Jan 31, 2023
Last Update Posted:
Jan 31, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Xiaomei Shao, Prof, The Third Affiliated hospital of Zhejiang Chinese Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2023